Copyright
©The Author(s) 2025.
World J Hepatol. Jun 27, 2025; 17(6): 108100
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.108100
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.108100
Table 1 Patient characteristics, n (%)
Characteristics | Short-course treatment | Long-course treatment | P value |
Age (median, IQR) | 78.0 (71.0-85.0) | 75.0 (69.0-84.0) | 0.667 |
Sex (male) | 13 (68.4) | 14 (56.0) | 0.599 |
Co-morbidities | |||
Cerebrovascular disease | 4 (21.1) | 6 (24.0) | 1.000 |
Chronic pulmonary disease | 4 (21.1) | 6 (24.0) | 1.000 |
Congestive heart failure | 2 (10.5) | 3 (12.0) | 1.000 |
Chronic liver disease | 1 (5.3) | 3 (12.0) | 0.622 |
Chronic kidney disease (serum creatinine > 1.5 mg/dL) | 2 (10.5) | 4 (16.0) | 0.684 |
Diabetes mellitus | 9 (47.4) | 9 (36.0) | 0.653 |
Rheumatic disease | 1 (5.3) | 0 (0) | 0.432 |
Malignancy | 1 (5.3) | 4 (16.0) | 0.370 |
Charlson Comorbidity Index (median, IQR) | 5.0 (4.5-7.0) | 6.0 (4.0-8.0) | 0.839 |
Use of other immunosuppressive agents or chemotherapy | 0 (0) | 1 (4.0) | 1.000 |
Use of glucocorticoids | 0 (0) | 2 (8.0) | 0.498 |
Tokyo Guideline 18 severity grading | 0.924 | ||
Grade Ⅰ | 7 (36.8) | 9 (36.0) | |
Grade Ⅱ | 4 (21.1) | 4 (16.0) | |
Grade Ⅲ | 8 (42.1) | 12 (48.0) | |
Quick Sepsis-Related Organ Failure Assessments (median, range) | 1 (0-3) | 2 (0-3) | 0.149 |
intensive care unit admission | 3 (15.8) | 7 (28.0) | 0.474 |
Use of vasopressor | 2 (10.5) | 8 (32.0) | 0.148 |
White blood cells at diagnosis (/mm3) (mean, range) | 9620 (2800-22900) | 12220 (3500-33100) | 0.217 |
C-reactive protein at diagnosis (mg/dL) (mean, range) | 7.09 (0.04-23.5) | 7.01 (0.05-29.0) | 0.915 |
Total bilirubin at diagnosis (mg/dL, mean, range) | 3.36 (1.0-7.4) | 3.18 (0.5-11.0) | 0.633 |
Body temperature (°C) (mean, range) | 37.9 (36.7-39.7) | 38.3 (36.6-40.7) | 0.229 |
Cause | 0.691 | ||
Stone | 16 (84.2) | 20 (80.0) | |
Diverticulum | 1 (5.3) | 3 (12.0) | |
Stent obstruction | 1 (5.3) | 2 (8.0) | |
Others | 1 (5.3) | 0 (0) | |
Acute cholecystitis | 9 (47.4) | 9 (36.0) | 0.653 |
Acute pancreatitis | 5 (26.3) | 3 (12.0) | 0.262 |
Heart valve disease | 7 (36.8) | 8 (32.0) | 0.988 |
Nosocomial onset | 1 (5.3) | 2 (8.0) | 1.000 |
Intravascular devices | 2 (10.5) | 2 (8.0) | 1.000 |
Auscultation of murmur | 0.844 | ||
Yes | 3 (16.7) | 2 (8.7) | |
No | 15 (83.3) | 21 (91.3) | |
Persistent fever for 7 days or more | 0 (0) | 0 (0) | |
Echocardiography | 7 (36.8) | 18 (72.0) | 0.042 |
Number of positive blood culture | 0.005 | ||
1 | 13 (68.4) | 6 (24.0) | |
2 | 6 (31.6) | 19 (76.0) | |
Follow-up of blood culture | 1.000 | ||
Positive | 0 (0) | 0 (0) | |
Negative | 4 (100) | 13 (100) | |
Causative organism | |||
Polymicrobial | 15 (79.0) | 17 (68.0) | 0.507 |
Enterococcus sp. | 13 (68.4) | 16 (64.0) | 1.000 |
Enterococcus faecalis | 4 (21.1) | 3 (12.0) | 0.443 |
Enterococcus faecium | 3 (15.8) | 2 (8.0) | 0.638 |
Streptococcus sp. | 6 (31.6) | 8 (32.0) | 1.000 |
Others | 1 (5.3) | 2 (8.0) | 1.000 |
Antibiotics | |||
Penicillin | 9 (47.4) | 23 (92.0) | 0.002 |
Cephalosporin | 13 (68.4) | 16 (64.0) | 1.000 |
Carbapenem | 2 (10.5) | 4 (16.0) | 0.684 |
Clindamycin | 8 (42.1) | 7 (28.0) | 0.511 |
Glycopeptide | 2 (10.5) | 11 (44.0) | 0.021 |
Fluoroquinolone | 5 (26.3) | 7 (28.0) | 1.000 |
Linezolid | 1 (5.3) | 0 (0) | 0.432 |
Metronidazole | 2 (10.5) | 1 (4.0) | 0.570 |
Aminoglycoside | 1 (5.3) | 0 (0) | 0.432 |
Time to drainage | 0.710 | ||
≤ 24 hours | 15 (78.9) | 21 (84.0) | |
> 24 hours | 4 (21.1) | 4 (16.0) | |
Duration of effective antibiotics days (median, IQR) | 9.0 (2.5-11.0) | 16.0 (15.0-19.0) | < 0.001 |
Duration of effective intravenous antibiotics days (median, IQR) | 8.0 (0.0-10.0) | 12.0 (8.0-16.0) | 0.001 |
- Citation: Kim Y, Ishikawa K, Nakamura K, Ikusaka H, Yokosuka R, Yamazaki T, Suzuki Y, Okuyama S, Takagi K, Fukuda K. Comparison between short-course and long-course antimicrobial treatments for acute cholangitis with gram-positive coccus bacteremia after endoscopic retrograde cholangiopancreatography. World J Hepatol 2025; 17(6): 108100
- URL: https://www.wjgnet.com/1948-5182/full/v17/i6/108100.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i6.108100